[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-inflammation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-inflammation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,78,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100569205","phase-2-effects-of-il-1-beta-inhibition-on-vascular-inflammation-in-tet2-clonal-hematopoiesis-100569205",false,"NCT06691217","Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis","TECTONIC","Inclusion Criteria:\n\n* 18 years or older\n* Coronary artery disease, defined as prior heart attack, coronary stent procedure \\>180 days before baseline imaging, or advanced subclinical coronary atherosclerosis (coronary artery calcium score ≥300 Agatston units, CAD-RADS 3 or greater atherosclerosis on coronary CT angiography, or qualitatively severe coronary artery calcification identified on non-gated CT imaging)\n* Presence of either TET2 mutations or no myeloid driver mutations on prior sequencing\n\nExclusion Criteria:\n\n* placement of a drug-eluting stent in a proximal coronary arterial segment \\\u003C180 days before baseline imaging\n* prior coronary artery bypass grafting\n* pregnancy or breastfeeding\n* history of blood malignancy or current solid-tumor malignancy\n* history of organ or stem cell transplantation\n* current treatment with prescription, systemic (oral, IV \\[intravenous\\], or IM \\[intramuscular\\]) steroids or anti-inflammatory\u002Fimmune suppressant medical therapies (including colchicine but excluding topical therapies, UV therapy, ASA-derivative therapies, or NSAIDS) for autoimmune\u002Finflammatory diseases, post-transplant care, asthma, or pain\n* use of oral steroids or prescription oral anti-inflammatory\u002Fimmune suppressant medication for \\>7 days within the past 1 month\n* use of IV or IM steroids or IV or IM anti-inflammatory\u002Fimmune suppressant medication within the past 3 months\n* known allergy to dextran's and\u002For DTPA and\u002For radiometals and\u002For severe allergy to iodinated contrast media\n* estimated glomerular filtration rate (eGFR) \\\u003C 45 ml\u002Fmin\u002F1.73 m2\n* contraindications to nitroglycerin known narrow angle glaucoma, or known severe aortic stenosis\n* use of phosphodiesterase type 5 inhibitor AND refusal to abstain from use of these medications within the 5 days prior to scheduled CCTA scan\n* significant radiation exposure (40msV) received within the past 12 months\n* concurrent enrollment in another research study judged by the investigators to interfere with the current study\n* known active or recurrent hepatic disease (including cirrhosis or ALT\u002FAST levels \\>3 times the upper limit oof or total bilirubin \\>2 times the upper limits of normal)\n* history or evidence of tuberculosis (TB) (active or latent) infection or risk factor for TB\n* active bacterial, fungal or viral infection at the time of enrollment or history of recurrent infections\n* suspected or proven immunocompromised state\n* live vaccinations within 3 months prior to randomization visit or live vaccinations planned during the trial","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coronary artery disease, including those with and without clonal hematopoiesis driven by mutations in TET2.",[26,27,28],"Vascular Inflammation","ASCVD","ASCVD Management",[30,31,32,26,27,33],"CHIP","TET2 CHIP","Clonal Hematopoiesis","ASCVD management","RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":38},"2026-03-24",{"date":42,"type":20},"2030-04-01",{"name":44,"class":45},"Massachusetts General Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100396593","improving-cardiovascular-risk-stratification-using-t1-mapping-in-general-population-100396593","NCT04444128","IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION","IMPReSSION","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. 18 years of age and over\n3. Absence of a valid clinical indication for CMR, and\u002For known or clinically relevant cardiac disease\n\nExclusion Criteria:\n\n* accepted contraindications for a contrast-enhanced CMR study (in line with MRI safety and SmPC for contrast agent)",true,{"count":56,"type":20},6000,"5 Years","OBSERVATIONAL","Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles, the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy, relationships with clinical characteristics, cardiovascular risk factors, routine cardiac imaging parameters, and prognosis. A further unknown relates to separation between healthy myocardium and subclinical disease in subgroups of patients with suspected cardiac involvement. Examples include patients with possible inflammation, such as in patients with a recent COVID-19 infection or vaccination. Anticipated recruitment of a total of 3000 subjects, with 1500 subjects per field strength (1.5 and 3.0 Tesla).",[61,62,63,26,64],"Myocarditis","Heart Failure","Myocardial Fibrosis","Long COVID Syndrome",[66,67,68],"Inflammation","Remodeling","vascular inflammation","2026-01-02",{"date":71,"type":38},"2026-01-06",{"date":73,"type":38},"2016-11-15",{"date":75,"type":20},"2030-06-30",{"name":77,"class":45},"Johann Wolfgang Goethe University Hospital",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":46},"100372409","high-resolution-high-speed-multimodal-ophthalmic-imaging-100372409","NCT04129021","High Resolution, High-speed Multimodal Ophthalmic Imaging","High Resolution and High Speed Multimodal Ophthalmic Imaging","IMA-MODE","Inclusion Criteria:\n\n* People over 18\n* Patient with a pathology affecting the eye or healthy volunteer\n* Participant who signed the consent\n* Beneficiaries of the health insurance\n\nExclusion Criteria:\n\n* Patients with a history of photosensitivity.\n* Patients who have just received a photodynamic therapy treatment (\n* Patients taking drugs with photosensitivity as a side effect.\n* Persons with pacemakers or other implanted electronic medical device\n* Patients with viral conjunctivitis or any other infectious disease.\n* Patients with skin lesions on the neck or forehead\n* Patients at high risk of damage from optical radiation, such as aphakic patients, or patients with decreased sensitivity to light due to fundus disease.\n* Pregnant or lactating women\n* Participant unable to be followed throughout the study\n* Vulnerable people\n* Subjects with predisposition to closure of the iridocorneal angle",{"count":87,"type":20},1200,[89],"NA","Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging. However, current clinical imaging systems are limited in resolution, speed, or access to certain structures of the eye.\n\nThe use of a high-resolution imaging system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many microstructures of the eye: photoreceptors, vessels, nerve bundles in the retina, cells and nerves in the cornea.\n\nThe use of a high-speed acquisition imaging system makes it possible to detect functional measurements such as the speed of blood flow. The combination of data from multiple imaging systems to obtain multimodal information is of great importance for improving the understanding of structural changes in the eye during a disease.\n\nThe purpose of this project is to observe structures that are not detectable with routinely used systems.",[92,93,94,95,96,97,98,26,99,100,101,102,103,104,105],"Retinitis Pigmentosa","Maculopathy, Age Related","Macular Dystrophy","Macular Edema","Retinal Detachment","Retinal Degeneration","Glaucoma","Hypertension","Stroke","Diabetes","Corneal Dystrophy","Keratoconus","Dry Eye","Trauma","2025-11-17",{"date":108,"type":38},"2025-11-18",{"date":110,"type":38},"2019-07-03",{"date":112,"type":20},"2027-07",{"name":114,"class":45},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":46},"100501707","phase-4-sgc-stimulation-perioperative-vascular-reactivity-and-organ-injury-in-cardiac-surgery-100501707","NCT05812755","SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery","The Effects of Soluble Guanylyl Cyclase Stimulation on Perioperative Vascular Reactivity and Organ Injury in Cardiac Surgery","SOLSTICE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Elective open-heart surgery, defined as surgery on the heart or aorta that requires sternotomy or thoracotomy\n\nExclusion Criteria:\n\n1. Intolerance to vericiguat\n2. Use of other soluble guanylyl cyclase stimulators or current use of phosphodiesterase-5 inhibitors\n3. Pregnancy or breast feeding. Pregnancy will be excluded in women of child-bearing potential by a urine or serum beta hcg test\n4. Renal replacement therapy within 30 days prior to screening\n5. Estimated glomerular filtration rate \\\u003C15 ml\u002Fmin per 1.73 m2 per Chronic Kidney Disease Epidemiology collaboration (CKD-EPI) equation at time of screening\n6. Systolic blood pressure less than 120 mmHg at the time of screening\n7. Prior kidney transplantation\n8. History of significant liver dysfunction (defined as Child-Pugh class C)\n9. Surgery scheduled to be performed with circulatory arrest\n10. Surgery scheduled to correct a major congenital heart defect\n11. Extracorporeal membrane oxygenation (ECMO) prior to surgery\n12. Active systemic infection or surgery for infectious endocarditis\n13. Ventricular assist device or intraaortic balloon pump support prior to surgery\n14. Prisoners",{"count":124,"type":20},170,[126],"PHASE4","The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are:\n\n1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo?\n2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo?\n\nParticipants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury.\n\nThis will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery.",[129,130,131,132,26],"Endothelial Dysfunction","Vascular Diseases","Kidney Injury","Brain Disease","2025-07-02",{"date":135,"type":38},"2025-07-08",{"date":137,"type":38},"2023-05-19",{"date":139,"type":20},"2027-11",{"name":141,"class":45},"Vanderbilt University Medical Center"]